ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Sanofi Finalizes Sale Of Dermik To Valeant Pharmaceuticals

PARIS -(Dow Jones)- French drug company Sanofi-Aventis (SAN.FR) announced Monday the finalization of the sale of its Canadian dermatology business, Dermik, to Valeant Pharmaceuticals International Inc. (VRX) for $422.5 million. In a statement, Sanofi said the transaction includes an aesthetic and therapeutic business in the U.S. and Canada, as well as an aesthetic business around the world. Sanofi's Canadian unit will continue its operations in Greater Montreal, said the company. -By Nadya Masidlover, Dow Jones Newswires; +33 1 4017 1740; nadya.masidlover@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
02/16/201708:29:00AstraZeneca to Get $130 Million Payment as Psoriasis Drug Siliq...
02/16/201707:00:00Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe P...
02/16/201707:00:00Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe P...
02/14/201717:59:34Statement of Ownership (sc 13g)
02/13/201717:00:00Valeant Pharmaceuticals To Participate At Healthcare Conferences
02/13/201717:00:00Valeant Pharmaceuticals To Participate At Healthcare Conferences
02/13/201716:36:52Amended Statement of Beneficial Ownership (sc 13d/a)
02/13/201716:34:45Current Report Filing (8-k)
02/07/201712:25:01Amended Statement of Ownership (sc 13g/a)
01/30/201716:30:00Valeant To Hold Conference Call To Present Fourth Quarter And...
01/30/201716:30:00Valeant To Hold Conference Call To Present Fourth Quarter And...
01/17/201718:19:00Allergan Admits to Disclosure Violations During Valeant Bid
01/11/201703:03:00Valeant Sheds Assets to Pay Down Debt -- WSJ
01/11/201703:03:00L'Oréal Expands Its Strategy -- WSJ
01/10/201717:11:00Current Report Filing (8-k)
01/10/201716:13:52Current Report Filing (8-k)
01/10/201714:31:00Valeant to Sell Skin-Care Brands to L'Oreal -- 2nd Update
01/10/201709:13:00L'Oréal Looks to Gain U.S. Share by Buying Valeant Brands...
01/10/201708:38:00L'Oréal Looks to Gain U.S. Share by Buying Valeant Brands
01/10/201706:00:00Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US